Therefore, it is speculated that highly upregulated VSIG3 in tumor cells could reinforce immune inhibitory signals to VISTA-expressing T cells in the tumor microenvironment, generating antibodies or chemical inhibitors that specifically block the VSIG3-VISTA interaction and could increase the efficiency of VISTA-based ICB therapy (22). Here, IGSF11 is linked to neoplasm.